1,1'- ((propane- 1,3- diyl)dioxy)bis(7- methoxy- 2- methylidene- 1,2,3,10,11,11a- hexahydro- 5H- pyrrolo(2,1- c)(1,4)benzodiazepin- 5,11- dione)

structure in first source

Also Known As:

NSC 694501; NSC-694501; NSC694501; SJG 136; SJG-136; SJG136; uglydimer1 cpd

Networked: 12 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione): 12
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        Benzodiazepinones
        1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione): 12

Experts

1.	Thurston, David E: 4 articles (01/2017 - 09/2004)
2.	Hartley, John A: 4 articles (06/2011 - 09/2004)
3.	Lee, Wooin: 3 articles (06/2011 - 01/2008)
4.	Spanswick, Victoria J: 3 articles (06/2011 - 09/2004)
5.	Calcutt, M Wade: 2 articles (06/2011 - 04/2010)
6.	Hachey, David L: 2 articles (06/2011 - 01/2008)
7.	Puzanov, Igor: 2 articles (06/2011 - 01/2008)
8.	Rothenberg, Mace L: 2 articles (06/2011 - 01/2008)
9.	Clingen, Peter H: 2 articles (03/2009 - 09/2004)
10.	Hochhauser, Daniel: 2 articles (03/2009 - 09/2004)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2011 - "Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors." 04/01/2010 - "We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor. " 04/01/2010 - "For patients with advanced solid tumors, the MTD of SJG-136 is 40 microg/m2/day administered on days 1, 8 and 15 of a 28-day cycle. " 01/01/2009 - "SJG-136 is currently undergoing Phase I evaluation in both the United States (through the NCI) and United Kingdom (through Cancer Research United Kingdom). " 01/01/2008 - "SJG-136 is highly cytotoxic in human tumor cells in vitro and in human tumor xenograft models in vivo at subnanomolar concentrations and is currently in anticancer phase I clinical trials in the United Kingdom and United States. "
2.	Ovarian Neoplasms (Ovarian Cancer) 06/01/2011 - "Coupled with supportive management, SJG-136 is now advancing to a phase II trial in ovarian cancer." 01/01/2017 - "The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clinical trials in patients with leukaemia and ovarian cancer. "
3.	Colonic Neoplasms (Colon Cancer) 08/01/2008 - "We previously showed that colon cancer cell lines expressing high levels of ABCB1 showed a lower sensitivity to SJG-136. " 08/01/2005 - "SJG-136 was highly potent in the colon cancer cell lines HCT-116, HT-29 and SW620 (IC50 0.1-0.3 nM). "
4.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/15/2004 - "Given this profile, we undertook a preclinical evaluation of SJG-136 in primary tumor cells derived from 34 B-cell chronic lymphocytic leukemia (B-CLL) patients. " 09/15/2004 - "The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill."
5.	Melanoma (Melanoma, Malignant) 09/15/2004 - "In the current investigation, SJG-136 was evaluated for in vivo efficacy in 10 tumor models selected on the basis of sensitivity of cells grown in the hollow fiber and in vitro time course assays: LOX IMVI and UACC-62 (melanomas); OVCAR-3 and OVCAR-5 (ovarian carcinomas); MDA-MB-435 (breast carcinoma); SF-295 and C-6 (gliomas); LS-174T (colon carcinoma); HL-60 TB (promyelocytic leukemia); and NCI-H522 (lung carcinoma). "

Related Drugs and Biologics

1.	1,1'- ((propane- 1,3- diyl)dioxy)bis(7- methoxy- 2- methylidene- 1,2,3,10,11,11a- hexahydro- 5H- pyrrolo(2,1- c)(1,4)benzodiazepin- 5,11- dione)
2.	DNA (Deoxyribonucleic Acid)
3.	Anthramycin (Antramycin)
4.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Intravenous Administration